Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma

15 Jul 2022

Abstract excerpt

Activating KRAS mutations occur in about 30% of pulmonary adenocarcinoma (AC) cases and the discovery of specific inhibitors of G12C-mutated KRAS has considerably improved the prognosis for a subgroup of about 14% of non-small cell lung cancer (NSCLC) patients. However, even in patients with a KRAS G12C mutation, the overall response rate only reaches about 40% and mutations other than G12C still cannot be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Lung Cancer Treatments and Mutations
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35888776
DOI: 10.3390/metabo12070652

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary AdenocarcinomaPMID 35888776Read ↗

KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.Semantic proximity Read ↗

A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the SpotlightSemantic proximity Read ↗

Oncogenic KRAS addiction states differentially influence MTH1 expression and 8-oxodGTPase activity in lung adenocarcinoma.Semantic proximity Read ↗

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cellsSemantic proximity Read ↗

More Than a Metabolic Enzyme: MTHFD2 as a Novel Target for Anticancer Therapy?Semantic proximity Read ↗

MTHFD2 in healthy and cancer cells: Canonical and non-canonical functionsSemantic proximity Read ↗

Enzymes of the one-carbon folate metabolism as anticancer targets predicted by survival rate analysisSemantic proximity Read ↗

Targeting GSTZ1 Sensitizes KRASG12C-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring.Semantic proximity Read ↗

Combinatorial targeting of MTHFD2 and PAICS in purine synthesis as a novel therapeutic strategySemantic proximity Read ↗

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.Semantic proximity Read ↗

The polyamine inhibitor SAM486A increases the efficacy of adagrasib in non-small cell lung cancer cells harboring KRASG12C mutation.Semantic proximity Read ↗

HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.